After 18-months patients averaged a 24 mmHg reduction in blood pressure measurements

ST. PAUL, Minn. - St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced new results from the EnligHTN I study, confirming safe, rapid and sustained reduction in blood pressure measurements a year and a half post-procedure. Data presented at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, indicates that patients with drug-resistant hypertension treated with the EnligHTN™ Multi-Electrode Renal Denervation System averaged a 24 mmHg (millimeters of mercury) reduction in systolic blood pressure as measured in an office setting.

"Convincing clinical evidence continues to emerge that supports the benefits of renal denervation in improving systolic blood pressure for patients with drug-resistant hypertension," said professor Stephen Worthley, from St. Andrew's Hospital in Adelaide, Australia, a primary investigator in the EnligHTN I trial, who delivered the findings at TCT. "The 18-month results of the EnligHTN I study point to an overall reduction in hypertension, which is important as even modest improvements can have significant health benefits for patients who live with this life-threatening condition. This also supports that the early reduction in blood pressure remains sustained out to 18-months, confirming the durability of this procedure using the EnligHTN catheter."
Eighteen-Month Data Findings:

An average systolic blood pressure reduction of 24 mmHg points was reported
The longer-term safety profile for renal denervation was supported by showing no clinically significant changes in kidney function
At 18-months, 77 percent of patients responded to the therapy, which is defined as a blood pressure reduction of at least 10 mmHg when measured during an office visit as compared to baseline

A prospective, multi-center feasibility study, the EnligHTN I trial treated 46 patients in Australia and Europe whose high blood pressure was considered drug-resistant despite taking three or more anti-hypertensive medications including a diuretic. Patients enrolled in the study had an average blood pressure of 176 / 96 mmHg and on average were taking 4.7 medications to control their hypertension. Patients in the study will continue to be followed for two years after their procedure.

Previous results from the EnligHTN I trial indicate an average reduction of 26 mmHg at six-months, 27 mmHg at one year and 24 mmHg at 18-months.

More HCB News